Dataset from A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/PR00009372
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to show that subcutaneous (SC) administration of daratumumab
co-formulated with recombinant human hyaluronidase PH20 (Dara SC) is non-inferior to
intravenous (IV) administration of daratumumab (Dara IV) in terms of the overall response
rate (ORR) and maximum trough concentration (Ctrough).
创建时间：
2026-04-09
